Charles River Laboratories announces launch of triple-immunodeficient mouse model for oncology research
Posted: 4 April 2017 | Charles River Laboratories | No comments yet
Charles River Laboratories International, Inc. (NYSE: CRL), a leading early-stage contract research organization (CRO), announced the North American launch of its triple-immunodeficient mouse model, known as the NCG model…
The NCG model is the first CRISPR-generated immunodeficient model offered by Charles River, and was developed by altering the Prkdc and Il2rg genes.
“The launch of Charles River’s NCG model provides a significant opportunity to assist our clients in the development of life-saving, translational therapies,” said Dr. Iva Morse, Corporate Vice President, Chief Scientific Officer, Global Research Models and Services. “The availability of this model, combined with our scientific expertise, will allow us to work with clients to advance the application of humanized studies in oncology, among other therapeutic areas.”
The NCG model was co-developed by the Nanjing Biomedical Research Institute of Nanjing University and Nanjing Galaxy Biopharma, and transferred to Charles River in 2016. The NCG model is similar to other triple-immunodeficient models in that it is capable of hosting xenograft cells, tissue, and human immune system components, enabling researchers to further study tumor biology and immuno-oncology.
Automation now plays a central role in discovery. From self-driving laboratories to real-time bioprocessing
This report explores how data-driven systems improve reproducibility, speed decisions and make scale achievable across research and development.
Inside the report:
- Advance discovery through miniaturised, high-throughput and animal-free systems
- Integrate AI, robotics and analytics to speed decision-making
- Streamline cell therapy and bioprocess QC for scale and compliance
- And more!
This report unlocks perspectives that show how automation is changing the scale and quality of discovery. The result is faster insight, stronger data and better science – access your free copy today
This model complements Charles River’s extensive portfolio of oncology products and services, including studies in human xenograft, syngeneic, and humanized immunotherapy research models, flow cytometry, and IVIS® imaging services. In November 2015, the Company acquired Oncotest GmbH, a Freiburg, Germany-based organization with a specialization in patient-derived xenograft (PDX) models, and in November 2016, partnered with OcellO to provide translational in vitro PDX and in vivo PDX oncology drug discovery services.
Charles River is introducing the NCG model to its North American customer base at the 2017 AACR Annual Meeting, which highlights the best cancer science and medicine from institutions all over the world. A full schedule of Charles River’s activities during the 2017 AACR Annual Meeting is available on their website, and reprints of each poster are available in Charles River’s booth (#1421) during the conference. Additionally, experts are available to discuss the NCG model, as well as their capabilities and expertise in oncology research. Throughout the conference, Charles River will be providing live updates on the Eureka Blog, including reviews of scientific sessions and input on the research being presented.
Related topics
CRISPR, Drug Discovery, Flow Cytometry, Oncology, Translational Science
Related organisations
Charles River Laboratories
Related people
Dr Iva Morse
